STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

LB100

RMC-6291-101

STX-721-101

StrateGIST 1 (IDRX-42-001)

D6900C00001

CA1201001

M22TGA

CTLR-101

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

D9570C00001

GO43860

XL092-001

SGNPDL1V-001

INCB 123667-101

PROACTIVE

1479-0001

CyPep-1

VHIO17002

MCLA-128-CL01

KEYNOTE 158

DESTINY-Lung03


<p>A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Participants with Advanced or Metastatic Solid Tumors</p>



<ul class="wp-block-list">
<li>Code NKI: M21AZD</li>



<li>Code firma: D9570C00001</li>



<li>Code clinicaltrials.gov: NCT04931654</li>
</ul>



<p><strong>Principal Investigator</strong></p>



<p>Dr. G. Ruiter</p>



<p><strong>Drugs </strong></p>



<p>AZD7789 (bispecific anti-PD-1/TIM3)</p>



<ul class="wp-block-list">
<li>NSCLC &#8211; <em>closed</em></li>



<li>Stomach &#8211; <em>closed</em></li>
</ul>



<h2 class="wp-block-heading"><strong>Summary</strong></h2>



<p>This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors</p>



<p>Read more on <a href="https://www.clinicaltrials.gov/ct2/show/NCT04931654?term=D9570C00001&amp;draw=2&amp;rank=1#contacts" data-type="URL" data-id="https://www.clinicaltrials.gov/ct2/show/NCT04931654?term=D9570C00001&amp;draw=2&amp;rank=1#contacts">clinicaltrials.gov</a></p>



<h3 class="wp-block-heading"><strong>Additional comments</strong></h3>



<p>The study is currently closed and it will open again.</p>



<h2 class="wp-block-heading"><br></h2>
